Reversal of subchronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5-HT6 receptor antagonist: Comparison among antipsychotics

Neuropsychopharmacology

Volumn 33, Issue 11, 2008, Pages 2657-2666

  Rodefer, Joshua S ^a   Nguyen, Tuyet N ^a   Karlsson, Jens Jakob ^b   Arnt, Jørn ^b  

^a E11 SSH   (United States)

^b H LUNDBECK A S   (Denmark)

Author keywords

5 HT6 receptor; Antipsychotic; Cognition; Executive function; Rat

Indexed keywords

5 CHLORO N [4 METHOXY 3 (1 PIPERAZINYL)PHENYL] 3 METHYL 2 BENZOTHIOPHENESULFONAMIDE; CLOZAPINE; HALOPERIDOL; OLANZAPINE; RISPERIDONE; SEROTONIN 6 ANTAGONIST; SERTINDOLE; VOLINANSERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION DEFICIT DISORDER; BRAIN FUNCTION; COGNITIVE DEFECT; CONTROLLED STUDY; DISRUPTIVE BEHAVIOR; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; TASK PERFORMANCE;

ANIMALS; ANTIPSYCHOTIC AGENTS; ATTENTION; IMIDAZOLES; INDOLES; MALE; PHENCYCLIDINE; RATS; RATS, LONG-EVANS; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 51749091526     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301654     Document Type: Article

References (67)

1. Abdul-Monim Z, Neill JC, Reynolds GP (2007). Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. J Psychopharmacol 21: 198-205.
2. Abdul-Monim Z, Reynolds GP, Neill JC (2006). The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behav Brain Res 169: 263-273.
3. Addington J, Addington D (1999). Neurocognitive and social functioning in schizophrenia. Schizophr Bull 25: 173-182.
4. Arnt J, Skarsfeldt T (1998). Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18: 63-101.
5. Azorin JM, Strub N, Loft H (2006). A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. Int Clin Psychopharmacol 21: 49-56.
6. Barense MD, Fox MT, Baxter MG (2002). Aged rats are impaired on an attentional set-shifting task sensitive to medial frontal cortex damage in young rats. Learn Mem 9: 191-201.
7. Bellack AS, Scholler NR, Marder SR, Kane JM, Brown CH, Yang Y (2004). Do clozapine and risperidone affect social competence and problem solving. Am J Psychiatry 161: 364-367.
8. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B et al (2002). Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperisdol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 159: 1018-1028.
9. Birrell JM, Brown VJ (2000). Medial frontal cortex mediates perceptual attentional set shifting in the rat. J Neurosci 20: 4320-4324.
10. Brewer W, Wood S, Phillips L, Francey S, Pantelis C, Yung A et al (2006). Generalized and specific cognitive performance in clinical high-risk cohorts: a review highlighting potential vulnerability markers for psychosis. Schizophr Bull 32: 538-555.
11. Chen KC, Baxter MG, Rodefer JS (2004). Central blockade of muscarinic cholinergic receptors disrupts affective and attentional set-shifting. Eur J Neurosci 20: 1081-1088.
12. Cleghorn JM, Kaplan RD, Szechtman B, Szechtman H, Brown GM (1990). Neuroleptic drug effects on cognitive function in schizophrenia. Schizophr Res 3: 211-219.
13. Cochran SM, Kennedy M, McKerchar CE, Steward LJ, Pratt JA, Morris BJ (2003). Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology 28: 265-275.
14. Cutmore TRH, Beninger RJ (1990). Do neuroleptics impair learning in schizophrenic patients. Schizophr Res 3: 173-186.
15. Dawson LA, Nguyen HQ, Li P (2001). The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology 25: 662-668.
16. Dias R, Robbins TW, Roberts AC (1996). Dissociation in prefrontal cortex of affective and attentional shifts. Nature 380: 69-72.
17. Didriksen M (1995). Effects of antipsychotics on cognitive behaviour in rats using the delayed non-match to position paradigm. Eur J Pharmacol 281: 241-250.
18. Didriksen M, Kreilgaard M, Arnt J (2006). Sertindole, in contrast to clozapine and olanzapine, does not disrupt water maze performance after acute or chronic treatment. Eur J Pharmacol 542: 108-115.
19. East SZ, Burnet PW, Leslie RA, Roberts JC, Harrison PJ (2002). 5-HT6 receptor binding sites in schizophrenia and following antipsychotic drug administration: autoradiographic studies with [125I]SB-258585. Synapse 45: 191-199.
20. Egerton A, Reid L, McKerchar CE, Morris BJ, Pratt JA (2005). Impairment in perceptual attentional set-shifting following PCP administration: a rodent model of set-shifting deficits in schizophrenia. Psychopharmacology 179: 77-84.
21. Eichenbaum HB, Ross R, Raji A, McGaughy JA (2003). Noradrenergic, but not cholinergic deafferentation of infralimbic/ prelimbic cortex impairs attentional set-shifting. Program No. 940.7. 2003 Abstract Viewer/Itinerary Planner Society for Neuroscience: Washington, DC. 2003. Online.
22. Featherstone RE, Rizos Z, Nobrega JN, Kapur S, Fletcher PJ (2007). Gestational methylazoxymethanol actate treatment impairs select cognitive functions: parallels to schizophrenia. Neuropsychopharmacology 32: 483-492.
23. Fitton A, Heel RC (1990). Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 40: 722-747.
24. Fox MT, Barense MD, Baxter MG (2003). Perceptual attentional set-shifting is impaired in rats with neurotoxic lesions of posterior parietal cortex. J Neurosci 23: 676-681.
25. Fulton B, Goa KL (1997). Olanzapine, a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 53: 281-298.
26. Gallhofer B, Jaanson P, Mittoux A, Tanghøj P, Lis S, Krieger S (2007). Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol. Pharmacopsychiatry 40: 275-286.
27. Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC, et al (2007). Cognitive improvement after treatment with second-generation antipsychotic medications in a first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry 64: 1115-1122.
28. Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar D et al (1993). The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 162: 43-48.
29. Green ME (2007). Cognition, drug treatment, and functional outcome in schizophrenia: a tale of two transitions. Am J Psychiatry 164: 992-994.
30. Green MF (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153: 321-330.
31. Green MF, Kern RS, Braff DL, Mintz J (2000). Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the 'right stuff'? Schizophr Bull 26: 119-136.
32. Harvey PD, Parrella M, White L, Mohs RC, Davidson M, Davis KL (1999). Convergence of cognitive and adaptive decline in late-life schizophrenia. Schizophr Res 35: 77-84.
33. Harvey PD, Rabinowitz J, Eerdekens M, Davison M (2005). Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry 162: 1888-1895.
34. Hatcher P, Brown V, Tait D, Bate S, Overend P, Hagan J et al (2005). 5-HT6 receptor antagonists improve performance in an attentional set shifting task in rats. Psychopharmacology 181: 253-259.
35. Hirst W, Stean T, Rogers D, Sunter D, Pugh P, Moss S et al (2006). SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur J Pharmacol 553: 109-119.
36. Hoff AL, Faustman WO, Wieneke M, Espinoza S, Costa M, Wilkowitz O et al (1996). The effect of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology 15: 361-369.
37. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308.
38. Jentsch JD, Roth RH (1999). The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20: 210-225.
39. Kane JM, Tamminga CA (1997). Sertindole (serdolect): preclinical and clinical findings of a new atypical antipsychotic. Exp Opin Investig Drugs 6: 1729-1741.
40. Keefe RSE, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM et al (2007). Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 64: 633-647.
41. Kraepelin E (1904). Lectures on Clinical Psychiatry. William Wood & Co: New York, NY. Lecture III: dementia praecox (pp. 21-29).
42. Lacroix L, Dawson L, Hagan J, Heidbreder C (2004). 5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex. Synapse 51: 158-164.
43. Lee S-M, Chou Y-H, Li M-H, Wan F-J, Yen M-H (2007). Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry doi 10.1016/j.pnpbp.03.016.
44. Leysen JE (2000). Receptor profile of antipsychotics. In: Ellenbroek BA, Cools AR (eds). Atypical Antipsychotics; Milestones In Drug Therapy. Birkhäuser Verlag: Basel, Boston, Berlin. pp 57-81.
45. Li Z, Huang M, Prus AJ, Dai J, Meltzer HY (2007). 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus. Brain Res 1134: 70-78.
46. Liegeois JF, Ichikawa J, Meltzer HY (2002). 5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res 947: 157-165.
47. McAlonan K, Brown VJ (2003). Orbital prefrontal cortex mediates reversal learning and not attentional set shifting in the rat. Behav Brain Res 146: 97-103.
48. Meltzer HY, McGurk SR (1999). The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25: 233-255.
49. Mitchell ES, Neumaier JF (2005). 5-HT6 receptors: a novel target for cognitive enhancement. Pharmacol Ther 108: 320-333.
50. Mork A, Witten LM, Arnt J (2007). Differentiating effects of sertindole and risperidone on extracellular levels of neurotransmitters in the frontal cortex of conscious rats. Program No.500. 13, 2007 Abstract Viewer/Itinerary Planner. Soc for Neurosci: San Diego, CA, 2007. Online.
51. Mortimer AM (1997). Cognitive function in schizophreniaFdo neuroleptics make a difference? Pharmacol Biochem Behav 56: 789-795.
52. Natesan S, Reckless G, Nobrega J, Fletcher P, Kapur S (2006). Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 31: 1854-1863.
53. Olsen CK, Bennum LT, Kreilgaard M (2006). Pharmacokinetic-pharmacodynamic modeling as a tool for prediction of therapeutic effective plasma levels in antipsychotics. Program No. 95. 15, 2006 Abstract Viewer/Itinerary Planner. Soc for Neurosci: Atlanta, GA, 2006. Online.
54. Pantelis C, Barber FZ, Barnes TRE, Nelson HE, Owen AM, Robbins TW (1999). Comparison of set-shifting ability in patients with chronic schizophrenia and frontal lobe damage. Schizophr Res 37: 251-270.
55. Remillard S, Pourcher E, Cohen H (2005). The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a 1-year follow up study. Schizophr Res 80: 99-106.
56. Rodefer JS (2006). The effects of antipsychotics on reversing PCP-induced deficits in a rodent attentional set-shifting task. Schizophr Res 81S: 130.
57. Rodefer JS, Murphy ER, Baxter MG (2005). PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur J Neurosci 21: 1070-1076.
58. Rodefer JS, Nguyen TN (2006). Naltrexone reverses age-induced cognitive deficits in rats. Neurobiol Aging, doi: 10.1016/j.neurobiolaging.2006.10. 005.
59. Sanchez C, Arnt J (2000). Assessment of 5-HT2A and 5-HT2C antagonistic properties of newer antipsychotics. Behav Pharmacol 11: 291-298.
60. Sanchez C, Kreilgaard M (2004). R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram. Pharmacol Biochem Behav 77: 391-398.
61. Skarsfeldt T (1996). Differential effect of antipsychotics on place navigation of rats in the Morris water maze. Psychopharmacology 124: 126-133.
62. Tamminga CA, Mack RJ, Granneman GR, Silber CJ, Kashkin KB (1997). Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety. Int Clin Psychopharmacol 12(Suppl 1): S29-S35.
63. Tollefson GD (1996). Cognitive function in schizophrenic patients. J Clin Psychiatry 57: 31-39.
64. Weinberger DR, Gallhofer B (1997). Cognitive function in schizophrenia. Int Clin Psychopharmacol 12: S29-S36.
65. Woolley ML, Marsden CA, Fone KCF (2004). 5-HT(6) receptors. Curr Drug Targets CNS Neurol Disord 3: 59-79.
66. Wunsch AM, Nguyen T, Guynn L, Rodefer JR (2006). Effects of 5-HT6 antagonists on attenuating PCP-induced cognitive deficits in a rodent set-shifting (ED/ID) task. Program No. 264.24, 2006 Abstract Viewer/Itinerary Planner. Soc for Neurosci: Atlanta, GA, 2006. Online.
67. Zhang W, Bymaster FP (1999). The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5-HT2A and muscarinic receptors. Psychopharmacology 141: 267-278.